Table 2.
Cases of thyroid involvement with multiple myeloma reported since 1994
| Author and year | Reference | Sex | Age | Localized or systemic | Associated thyroid disease | Other comments |
|---|---|---|---|---|---|---|
| Sahu et al., 2019 | [26] | Male | 57 | Systemic | No | |
| Gochhait et al., 2019 | [27] | Male | 57 | Systemic | No | |
| Singh et al., 2017 | [28] | Male | 57 | Systemic | No | Initially normal bone marrow |
| Park et al., 2010 | [29] | Female | 68 | Systemic | No | |
| Ozdemir et al., 2009 | [30] | Male | 57 | Systemic | No | Relapse site of multiple myeloma |
| Serefhanoglu et al., 2008 | [31] | Female | 76 | Systemic | No | |
| Terrier et al., 2006 | [32] | Female | 78 | Systemic | No | Relapse site of multiple myeloma, responded to thalidomide and dexamethasone |
| Wahner-Roedler et al., 2003 | [33] | Female | 87 | Systemic | No | |
| Bourtsos et al., 2000 | [34] | Male | 73 | Systemic | No | |
| Schiller et al., 1995 | [35] | Male | 68 | Systemic | No | |
| Vailati et al., 1995 | [36] | Female | 55 | Systemic | No |